

TITLE OF THE INVENTION

COMPOSITIONS AND METHODS OF  
DOUBLE-TARGETING VIRUS INFECTIONS AND CANCER CELLS

5

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of copending U.S. Application  
Serial No. 09/693,658, entitled "Compositions and Methods for Double-Targeting  
Virus," filed on October 19, 2000 in the names of Louis S. Kucera, Ronald A. Fleming,  
10 Khalid S. Ishaq, Gregory L. Kucera, and Susan L. Morris-Natschke. The entirety of  
that earlier-filed, co-pending application is hereby expressly incorporated by reference.

STATEMENT REGARDING FEDERALLY SUPPORTED  
RESEARCH AND DEVELOPMENT

This research was supported in part by U.S. Government funds  
15 (National Cancer Institute Grant No. CA12197), and the U.S. Government may  
therefore have certain rights in the invention.

BACKGROUND OF THE INVENTION

Acquired immunodeficiency syndrome (AIDS) is a degenerative disease  
of the immune system and central nervous system (CNS) resulting from infection of  
20 humans by HIV virus. AIDS is responsible for a rapidly growing fatality rate in the  
world population. At present, no cure has been found, and clinically approved drugs  
are limited in number. These drugs include nucleoside reverse transcriptase (RT)  
inhibitors such as 3'-azido-3'-deoxythymidine (AZT, Zidovudine), dideoxyinosine (ddI,  
Didanosine), dideoxycytidine (ddC, Zalcitabine), 2', 3'-dideoxy-3'-thiacytidine (3TC,  
25 Lamivudine), and 2', 3'-didehydro-3'-deoxythymidine (d4T, Stavudine), a non-  
nucleoside RT inhibitor (Niverapine), and protease inhibitors such as saquinavir  
(Inverase), ritonavir (Norvir), indinavir (Crixivan), and nelfinavir (Viracept).

5 Nucleoside RT inhibitors generally have similar structures (2', 3'-dideoxynucleosides) and act at an early stage in virus replication to inhibit provirus DNA synthesis (De Clercq, 1995, *Journal of Medicinal Chemistry*, 38:2491-2517). However, AZT, the recommended initial therapeutic agent, and the other nucleoside analogues have several limitations, including adverse side effects such as bone marrow depression and anemia (Gill et al., 1987, *Annals of Internal Medicine*, 107:502-505; Richman et al., 1987, *New England Journal of Medicine*, 317:192-197). Peripheral neuropathy is also a major and common side effect. AZT is rapidly eliminated from the plasma with a half-life of about one hour (Surbone et al., 1988, *Annals of Internal Medicine*, 108:534-540) and is quickly metabolized in the liver to its corresponding 5'-glucuronide, which is inactive.

10 Presently, only a small number of antiviral drugs are available for treatment of virus infections. A complication to the development of such drugs is that mutant strains of virus which are resistant to currently available antiviral drugs are developing at an alarming rate. Combinations of new drugs having unique modes of action are urgently needed to replace drugs that have lost their potency against viruses as a result of virus mutations. A further complication to the development of antiviral drugs is that development of viral resistance to available compounds is not the same in different body compartments and fluids. For example, evolution of drug resistance among HIV-1 clinical isolates is often discordant in blood and semen of HIV-1 positive males (Eron et al., 1998, *AIDS* 12:F181-F189).

20 Further, currently available drugs useful for antiviral therapy sometimes ineffectively penetrate the genital tract. This is a serious drawback to the use of these drugs to combat viruses which infect the genital tract. If an antiviral drug promotes development of resistance in the genital tract and the virus is commonly transmitted from this body site, the drug will rapidly become ineffective for treatment of the virus infection in the population at risk for transmission. Hence, drug-resistant mutants of

5 certain viruses can be rapidly spread by sexual contact in the human population. It is known that viruses such as HIV, hepatitis B, hepatitis C, herpes simplex virus, cytomegalovirus, papilloma viruses, and many others are transmitted via sexual contact by both males and females. Thus, therapeutic drugs that fully suppress virus infections in the genital tract are a high public health priority.

Another limitation of presently available antiviral drugs is that rapid emergence of drug resistant mutant virus can lead to decreased sensitivity to the drug within a patient or within a patient population (Larder et al., 1989, Science, 243:1731-1734). Thus, the beneficial effects of drugs such as AZT are limited in duration.

10 The anti-HIV chemotherapy era which started a decade ago has recently made significant progress toward better control of HIV-1 infection by the introduction of protease inhibitors and the use of combinations of nucleoside and non-nucleoside RT inhibitors with protease inhibitors. Monotherapy (e.g. administration of a single drug) using a nucleoside or non-nucleoside RT inhibitor or a protease inhibitor is no  
15 longer a recommended form of therapy for treatment of a patient with a virus infection such as HIV-1 infection. Although combinations of AZT, 3TC, and a protease inhibitor have reduced virus load in the plasma of patients to below detectable levels (i.e. fewer than 200 copies of viral RNA per milliliter of plasma) with a concomitant increase in CD4<sup>+</sup> cell count, some drug combinations have been associated with  
20 increased toxicity in a person receiving multiple drug therapies. Also, although reduction in virus burden in the plasma of patients to non-detectable levels achieved using some drug combinations is impressive, drug resistance is an escalating problem due to both use and misuse of drug therapy (De Clercq, 1995, Journal of Medicinal Chemistry, 38:2491-2517; Bartlett, 1996, Infectious Diseases in Clinical Practice, 5:172-179) and evolution of resistant mutants in blood and seminal fluids (Eron et al.,  
25 1998, AIDS, 12:F181-F189).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
2224  
2225  
2226  
2227  
2228  
2229  
2230  
2231  
2232  
2233  
2234

suggests that INK-11 induces production of defective virus, similar to the effect achieved using other lipid compounds alone (Kucera, et al., 1990, AIDS Research & Human Retroviruses 6:491-501).

Other synthetic phospholipids which do not comprise a phosphocholine moiety (non-PC lipids) have been conjugated with antiviral chemotherapeutic agents. For example, thioether lipid-nucleoside conjugates have exhibited improved antineoplastic activity in tumor-bearing mice (Hong et al., 1990, Journal of Medicinal Chemistry 33:1380-1386). Also, natural phospholipids coupled to AZT or to dideoxynucleosides (ddT, ddC) have proven to be markedly active against HIV by inhibiting viral RT activity (Steim et al., 1990, Biochemical & Biophysical Research Communications 171:451-457; Hostetler et al., 1990, Journal of Biological Chemistry 265:6112-6117; Hostetler et al., 1991, Journal of Biological Chemistry 266:11714-11717). Studies of phospholipid antiviral efficacy have also included chemically conjugating AZT or ddI, through a phosphate-ester bond, to selected synthetic phosphatidic acid lipid analogues (Piantadosi et al., 1991, Journal of Medicinal Chemistry 34:1408-1414). Synthetic phosphate-ester linked lipid-nucleoside conjugates were found to be markedly active against infectious HIV-1 production in both acutely- and persistently- infected cells, and were 5- to 10-fold less cytotoxic compared with AZT alone (Piantadosi et al., 1991, Journal of Medicinal Chemistry 34:1408-1414). Results of preliminary studies indicated that synthetic lipid-AZT conjugates block reactivity of HIV-1-induced gp160/gp120 proteins with specific monoclonal antibodies on the surface of infected and treated cells and on the surface of treated HIV-1 particles, as measured by flow cytometry. These conjugate compounds also caused inhibition of HIV-1-induced cell fusion (Kucera et al., 1992, In: Novel Membrane Interactive Ether Lipids With Anti-Human Immunodeficiency Virus Activity, Aloia et al., eds., Membrane Interactions of HIV, pp.329-350; Krugner-Higby et al., 1995, AIDS Research & Human Retroviruses 11:705-712). However, these

phosphate ester-linked lipid-AZT conjugates (non-PC lipid-AZT conjugates) were not very active against AZT-resistant clinical isolates of HIV-1. Moreover, after intracellular metabolism of the conjugate with resulting release of AZT-monophosphate, the lipid moiety exhibited only moderate to non-detectable antiviral activity (Piantadosi et al., 1991, Journal of Medicinal Chemistry 34:1408-1414).

As with the antiviral agents, the development of anticancer agents for treating cancer effectively has also been problematic. Barriers such as cellular mechanisms of anticancer drug resistance, overcoming the blood-brain barrier to provide adequate delivery of drug to the brain and CNS, inadequate uptake of drug by lymphoid and hematopoietic tissues, toxicity, achieving oral bioavailability, overcoming short drug half-life, and preventing extracellular metabolism of the anticancer agent are faced by the skilled artisan.

In order to improve bioavailability to CNS and brain tissue, nucleoside analogues have been encapsulated in liposomes or used with modifying agents to disrupt the blood-brain barrier (Braekman, et al., 1997, Proc. Amer. Soc. for Clinical Oncology, Abstract #810). Implantable devices have been used to provide more sustained drug delivery to increase the pharmacokinetics of anticancer agents (Del Pan, et al., 1997, Proc. Amer. Soc. for Clinical Oncology, Abstract #1384). Additionally, attempts to improve the efficacy of nucleoside analogues in cancer therapy have included the use of multidrug combinations and high-dose nucleoside analogue therapy (Capizzi, 1996, Investigational New Drugs 14:249-256). None of these methods have adequately overcome the problems discussed above with regard to anticancer agents.


Another attempt to circumvent the problems associated with conventional nucleoside analogue cancer therapy has been the conjugation of these molecules to phospholipids. Thus far, the conjugation of nucleoside analogues to phospholipid molecules has focused on ara-C and a limited number of diacyl, alkylacyl and thioether phospholipids (Hong, 1990, Cancer Res. 50:4401-4406). Although these

conjugates have shown efficacy in the treatment of hematologic malignancies, these drugs must be administered intraperitoneally or intravenously and do not overcome the problems discussed above regarding anticancer agents. These conjugates are degraded by phospholipase A and phospholipase B extracellularly and do not provide the option of oral administration.

Despite the promising attributes of compounds such as PC lipids, and non-PC lipid-nucleoside analogue conjugates, currently available antiviral and anticancer agents such as nucleoside analogues and anti-HIV nucleoside drugs have severe inherent limitations. Although such drugs are capable of delaying the onset of symptoms of virus infection and extending survival time for patients, new compounds having the attributes of increased tolerability, potency, and selectivity against specific viruses, differential mechanisms of action, ability to cross the blood-brain barrier, and freedom from myelosuppressive side effects are urgently needed for improved treatment of virus infections. Also, new antiviral and anticancer compounds are needed which more effectively combat cancers or target multiple aspects of the virus life cycle, which facilitate delivery of an anticancer agent to cells and tissues not normally accessible to anticancer agents (e.g. CNS and lymphoid tissues), which combine lipophilic (e.g. phospholipid) and antiretroviral or anticancer agents within the same molecule (e.g. conjugate compounds) in order to yield a drug with a more sustained antiviral or anticancer effect, which decrease the rate of emergence of drug-resistant virus strains, and which inhibit virus replication in a wider range of cellular or tissue reservoirs of virus infection. The present invention satisfies these needs.

#### BRIEF SUMMARY OF THE INVENTION

The invention includes a compound having the structure of Formula III:



(III)

wherein,

$\text{R}^{11}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;

$\text{R}^{12}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;

$\text{R}^{12'}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl, alkynyl, aryl, phenalkyl, or alkoxy or hydroxy, anhydride, or hydrogen, with the proviso that when  $\text{R}^{12'}$  is not hydroxy, it is optionally linked to  $\text{X}^{12}$  through a linker moiety L and wherein  $\text{R}^{12'}$  is optionally terminally substituted with a therapeutic agent, wherein

L is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$\text{X}^{11}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$\text{X}^{12}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$\text{X}^{13}$  is -O-, -S-, -CH<sub>2</sub>-, anhydride, or (C<sub>1</sub>-C<sub>16</sub>) alkoxy;

n is 0, 1 or 2;

$\text{R}^{13}$  is a therapeutic agent or -R<sup>3</sup>N(R<sup>6</sup>)(R<sup>7</sup>)R<sup>8</sup>;

R<sup>3</sup> is (C<sub>1</sub>-C<sub>8</sub>) alkylene; and

R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each independently -H, (C<sub>1</sub>-C<sub>8</sub>) alkyl or (C<sub>1</sub>-C<sub>8</sub>)


alkoxy;

and pharmaceutically acceptable salts and prodrugs thereof.



The invention includes another compound having the structure of

Formula III:



(III)

wherein,

$\text{R}^{11}$  is  $(\text{C}_1\text{-C}_{16})$  alkyl, branched alkyl, alkenyl or alkynyl;

$\text{R}^{12}$  is  $(\text{C}_1\text{-C}_{16})$  alkyl, branched alkyl, alkenyl or alkynyl;

$\text{R}^{12'}$  is  $(\text{C}_1\text{-C}_{16})$  phenalkyl or alkoxy or anhydride or hydroxy, with the

proviso that when  $\text{R}^{12'}$  is not hydroxy, it is linked to  $\text{X}^{12}$  through an ether oxygen and wherein  $\text{R}^{12'}$  is terminally substituted with a therapeutic agent;

$\text{X}^{11}$  is -S-;

$\text{X}^{12}$  is -O-;

$\text{X}^{13}$  is -O-;

$\text{R}^{13}$  is  $-\text{R}^3\text{N}(\text{R}^6)(\text{R}^7)\text{R}^8$ ;


$\text{R}^3$  is  $-\text{CH}_2\text{CH}_2-$ ; and

$\text{R}^6$ ,  $\text{R}^7$  and  $\text{R}^8$  are each independently methyl;

and pharmaceutically acceptable salts and prodrugs thereof.

The invention includes another compound having the structure of

Formula III:



(III)

5 wherein,

$\text{R}^{11}$  is  $-\text{C}_{12}\text{H}_{25}$ ;

$\text{R}^{12}$  is  $-(\text{CH}_2)_8$ ,  $-(\text{CH}_2)_{10}$ , or  $-(\text{CH}_2)_{12}$ ;

$\text{R}^{12'}$  is  $-\text{O}_2\text{CCH}_2\text{CO}_2\text{AZT}$ ;

$\text{X}^{11}$  is  $-\text{S}-$ ;

10  $\text{X}^{12}$  is  $-\text{O}-$ ;

$\text{X}^{13}$  is  $-\text{O}-$ ;


$\text{R}^{13}$  is  $-\text{R}^3\text{N}(\text{R}^6)(\text{R}^7)\text{R}^8$ ;

$\text{R}^3$  is  $-\text{CH}_2\text{CH}_2-$ ; and

$\text{R}^6$ ,  $\text{R}^7$  and  $\text{R}^8$  are each independently methyl;

15 and pharmaceutically acceptable salts and prodrugs thereof.

The invention also includes a method of treating a virus infection in a mammal. The method comprises administering to the mammal, in an amount effective to treat the infection, a compound, or a pharmaceutically acceptable salt or a prodrug thereof, having the structure of Formula III:



(III)


wherein,

- 5             $\text{R}^{11}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;  
               $\text{R}^{12}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;  
               $\text{R}^{12'}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl, alkynyl, aryl, phenalkyl,  
              or alkoxy or hydroxy, anhydride, or hydrogen, with the proviso that when  $\text{R}^{12'}$  is not  
              hydroxy, it is optionally linked to  $\text{X}^{12}$  through a linker moiety L and wherein  $\text{R}^{12'}$  is  
 10        optionally terminally substituted with a therapeutic agent, wherein  
              L is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;  
               $\text{X}^{11}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;  
               $\text{X}^{12}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;  
               $\text{X}^{13}$  is -O-, -S-, -CH<sub>2</sub>-, anhydride, or (C<sub>1</sub>-C<sub>16</sub>) alkoxy;  
 15        n is 0, 1 or 2;  
               $\text{R}^{13}$  is a therapeutic agent or -R<sup>3</sup>N(R<sup>6</sup>)(R<sup>7</sup>)R<sup>8</sup>;  
              R<sup>3</sup> is (C<sub>1</sub>-C<sub>8</sub>) alkylene; and  
              R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each independently -H, (C<sub>1</sub>-C<sub>8</sub>) alkyl or (C<sub>1</sub>-C<sub>8</sub>)

alkoxy.

The invention also includes a method of inhibiting virus replication in a cell. The method comprises administering to the cell, in an amount effective to inhibit virus replication in the cell, a compound, or a pharmaceutically acceptable salt or a prodrug thereof, having the structure of Formula III:

5



(III)

wherein,

- 10  $\text{R}^{11}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;  
 $\text{R}^{12}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;  
 $\text{R}^{12'}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl, alkynyl, aryl, phenalkyl,  
or alkoxy or hydroxy, anhydride, or hydrogen, with the proviso that when  $\text{R}^{12'}$  is not  
hydroxy, it is optionally linked to  $\text{X}^{12}$  through a linker moiety L and wherein  $\text{R}^{12'}$  is  
optionally terminally substituted with a therapeutic agent, wherein

- 15 L is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;  
 $\text{X}^{11}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;  
 $\text{X}^{12}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;  
 $\text{X}^{13}$  is -O-, -S-, -CH<sub>2</sub>-, anhydride, or (C<sub>1</sub>-C<sub>16</sub>) alkoxy;  
n is 0, 1 or 2;


$R^{13}$  is a therapeutic agent or  $-R^3N(R^6)(R^7)R^8$ ;

$R^3$  is  $(C_1-C_8)$  alkylene; and

$R^6$ ,  $R^7$  and  $R^8$  are each independently -H,  $(C_1-C_8)$  alkyl or  $(C_1-C_8)$

alkoxy.

5 The invention also includes a method of combating a cancer in a mammal. The method comprises administering to the mammal, in an amount effective to combat a cancer in the mammal, a compound, or a pharmaceutically acceptable or a prodrug salt thereof, having the structure of Formula III:



(III)

wherein,

$R^{11}$  is  $(C_1-C_{16})$  alkyl, branched alkyl, alkenyl or alkynyl;

$R^{12}$  is  $(C_1-C_{16})$  alkyl, branched alkyl, alkenyl or alkynyl;

15  $R^{12'}$  is  $(C_1-C_{16})$  alkyl, branched alkyl, alkenyl, alkynyl, aryl, phenalkyl, or alkoxy or hydroxy, anhydride, or hydrogen, with the proviso that when  $R^{12'}$  is not hydroxy, it is optionally linked to  $X^{12}$  through a linker moiety L and wherein  $R^{12'}$  is optionally terminally substituted with a therapeutic agent, wherein

L is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{11}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{12}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{13}$  is -O-, -S-, -CH<sub>2</sub>-, anhydride, or (C<sub>1</sub>-C<sub>16</sub>) alkoxy;

n is 0, 1 or 2;


5  $R^{13}$  is a therapeutic agent or -R<sup>3</sup>N(R<sup>6</sup>)(R<sup>7</sup>)R<sup>8</sup>;

$R^3$  is (C<sub>1</sub>-C<sub>8</sub>) alkylene; and

$R^6$ ,  $R^7$  and  $R^8$  are each independently -H, (C<sub>1</sub>-C<sub>8</sub>) alkyl or (C<sub>1</sub>-C<sub>8</sub>)

alkoxy.

10 The invention further includes a method of treating a disease in a mammal. The method comprises administering to the mammal, in an amount effective to treat the disease, a compound, or a pharmaceutically acceptable salt or a prodrug thereof, having the structure of Formula III:



(III)

15

wherein,

$R^{11}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;

$R^{12}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;

$R^{12'}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl, alkynyl, aryl, phenalkyl,

or alkoxy or hydroxy, anhydride, or hydrogen, with the proviso that when  $R^{12'}$  is not hydroxy, it is optionally linked to  $X^{12}$  through a linker moiety L and wherein  $R^{12'}$  is optionally terminally substituted with a therapeutic agent, wherein

L is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{11}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{12}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{13}$  is -O-, -S-, -CH<sub>2</sub>-, anhydride, or (C<sub>1</sub>-C<sub>16</sub>) alkoxy;

n is 0, 1 or 2;


$R^{13}$  is a therapeutic agent or -R<sup>3</sup>N(R<sup>6</sup>)(R<sup>7</sup>)R<sup>8</sup>;

$R^3$  is (C<sub>1</sub>-C<sub>8</sub>) alkylene; and

$R^6$ ,  $R^7$  and  $R^8$  are each independently -H, (C<sub>1</sub>-C<sub>8</sub>) alkyl or (C<sub>1</sub>-C<sub>8</sub>)

alkoxy.

The invention also includes a pharmaceutical composition comprising a compound and a pharmaceutically acceptable carrier, the compound having the structure of Formula III:



(III)

wherein,

$R^{11}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;

$R^{12}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;

$R^{12'}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl, alkynyl, aryl, phenalkyl,  
or alkoxy or hydroxy, anhydride, or hydrogen, with the proviso that when  $R^{12'}$  is not  
5 hydroxy, it is optionally linked to  $X^{12}$  through a linker moiety L and wherein  $R^{12'}$  is  
optionally terminally substituted with a therapeutic agent, wherein

L is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{11}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{12}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

10  $X^{13}$  is -O-, -S-, -CH<sub>2</sub>-, anhydride, or (C<sub>1</sub>-C<sub>16</sub>) alkoxy;

n is 0, 1 or 2;

$R^{13}$  is a therapeutic agent or -R<sup>3</sup>N(R<sup>6</sup>)(R<sup>7</sup>)R<sup>8</sup>;


R<sup>3</sup> is (C<sub>1</sub>-C<sub>8</sub>) alkylene; and

15  $R^6$ ,  $R^7$  and  $R^8$  are each independently -H, (C<sub>1</sub>-C<sub>8</sub>) alkyl or (C<sub>1</sub>-C<sub>8</sub>)  
alkoxy;

and pharmaceutically acceptable salts and prodrugs thereof.

The invention also includes another pharmaceutical composition  
comprising a compound and a pharmaceutically acceptable carrier, the compound  
having the structure of Formula III:





(III)

wherein,

$\text{R}^{11}$  is  $(\text{C}_1\text{-C}_{16})$  alkyl, branched alkyl, alkenyl or alkynyl;

$\text{R}^{12}$  is  $(\text{C}_1\text{-C}_{16})$  alkyl, branched alkyl, alkenyl or alkynyl;

$\text{R}^{12'}$  is  $(\text{C}_1\text{-C}_{16})$  phenalkyl or alkoxy or anhydride or hydroxy, with the proviso that when  $\text{R}^{12'}$  is not hydroxy, it is linked to  $\text{X}^{12}$  through an ether oxygen and wherein  $\text{R}^{12'}$  is terminally substituted with a therapeutic agent;

$\text{X}^{11}$  is -S-;

$\text{X}^{12}$  is -O-;

$\text{X}^{13}$  is -O-;


$\text{R}^{13}$  is  $-\text{R}^3\text{N}(\text{R}^6)(\text{R}^7)\text{R}^8$ ;

$\text{R}^3$  is  $-\text{CH}_2\text{CH}_2-$ ; and

$\text{R}^6$ ,  $\text{R}^7$  and  $\text{R}^8$  are each independently methyl;

and pharmaceutically acceptable salts or prodrugs thereof.

The invention also includes another pharmaceutical composition comprising a compound and a pharmaceutically acceptable carrier, the compound having the structure of Formula III:



(III)

wherein,

$\text{R}^{11}$  is  $-\text{C}_{12}\text{H}_{25}$ ;

$\text{R}^{12}$  is  $-(\text{CH}_2)_8$ ,  $-(\text{CH}_2)_{10}$ , or  $-(\text{CH}_2)_{12}$ ;

$\text{R}^{12'}$  is  $-\text{O}_2\text{CCH}_2\text{CO}_2\text{AZT}$ ;

$\text{X}^{11}$  is  $-\text{S}-$ ;

$\text{X}^{12}$  is  $-\text{O}-$ ;

$\text{X}^{13}$  is  $-\text{O}-$ ;

$\text{R}^{13}$  is  $-\text{R}^3\text{N}(\text{R}^6)(\text{R}^7)\text{R}^8$ ;

$\text{R}^3$  is  $-\text{CH}_2\text{CH}_2-$ ; and

$\text{R}^6$ ,  $\text{R}^7$  and  $\text{R}^8$  are each independently methyl;

and pharmaceutically acceptable salts and prodrugs thereof.

### BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings.

sub  
01  
Figure 1, comprising Figures 1A, 1B, 1C and 1D is a series of formulae depicting the chemical structures of several anticancer agents. Figure 1A depicts the chemical structure of BM21.1290. Figure 1B depicts the chemical structure of gemcitabine. Figure 1C depicts the chemical structure of ara-C. Figure 1D depicts the chemical structure of 5-azacytidine.

Figure 2 is a reaction scheme depicting the synthesis method for preparing a lipid backbone (i.e. an alkyl lipid) for the compounds of the invention.


Figure 3 is a reaction scheme depicting the synthesis method for preparing an AZT-malonic acid (AZT-MA) compound, which is an intermediate compound in the synthesis of the double targeting PC lipid-AZT conjugate compounds of the invention.


Figure 4 is a reaction scheme depicting the synthesis method for preparing a double targeting PC lipid-AZT conjugate compound of the invention (INK-20).

Figure 5 is a graph depicting the concentrations of radiolabeled BM21.1290 in plasma and various lymphoid tissue samples after administration of radiolabeled BM21.1290 to female C57BI/6 mice for a two week period. The data indicate the preferential uptake of BM21.1290 into lymphoid tissue of mice.

Figure 6 is a graph depicting the concentrations of radiolabeled BM21.1290 in plasma and brain tissue samples after administration of different doses of radiolabeled BM21.1290 to female C57BI/6 mice for a two week period. The data indicate that the concentration of BM21.1290 in brain tissue samples is equivalent to the concentration of the compound in plasma, indicating that the compound effectively crosses the blood-brain barrier in mice.

sub  
02  
Figure 7, comprising Figures 7A and 7B, is a pair of formulae depicting the chemical structures of exemplary compounds of Formula III.

*Sub 2*  
*13*  **Figure 8**, comprising Figures 8A and 8B, is a pair of formulae depicting the chemical structures of exemplary compounds of Formula IV.

*Sub 1*  
*5*  **Figure 9** is a formula depicting the chemical structure of an exemplary compound of Formula V.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to methods and compositions useful in drug delivery for treatment of a virus infection in a mammal by targeting the virus at two or more stages of the virus life cycle and thereby inhibiting virus replication. This mode of use of antiviral compositions is referred to herein as double-targeting a virus infection. The compositions of the invention include compounds comprising at least two chemically combined (e.g. covalently conjugated) antiviral agents which have different modes of action. Because the antiviral agents have different modes of action, they target the virus life cycle at two or more different stages. By way of example and not by limitation, the compositions of the invention include compounds having a nucleoside analogue or protease inhibitor moiety conjugated with a phosphocholine lipid (PC lipid) moiety. Also by way of example and not by limitation, the targets in the viral life cycle of the compounds of the invention may include stages involving reverse transcription, protease activity, and virus assembly. The methods and compositions of the invention are particularly useful in combating drug-resistant mutants of viruses because viruses resistant to nucleoside analogues and protease inhibitors are still sensitive to inhibition by phospholipids. As used herein, the term "conjugated with" means covalently attached to the same molecule.

The targeted virus may be any type of virus, and non-limiting exemplary viruses include HIV-1, HIV-2, hepatitis virus (e.g. hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E viruses), and herpesviruses (e.g. herpes simplex

virus types 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein Barr virus, and human herpes viruses types 6, 7, and 8).

The compounds of the invention exhibit biological properties which are superior to currently available antiviral drugs, including (i) reduced cytotoxicity  
5 accompanied by the ability of the mammal to tolerate a higher dose of the drug compared with nucleoside analogues or protease inhibitors alone, (ii) ability to target multiple distinct stages of virus replication (e.g. reverse transcription, protease processing of viral proteins and virus assembly, leading to non-replication or to production of defective progeny virus) (iii) ability to simultaneously deliver constant  
10 amounts of multiple antiviral agents (e.g. phosphocholine lipid and a nucleoside analogue or phosphocholine lipid and a protease inhibitor) to virus-infected cells with preferential uptake into the CNS, lymphoid tissues, and male and female genital tracts, (iv) intracellular metabolism of the conjugate compound and simultaneous release of two antiviral agents in cells in which virus is multiplying, (v) increased half-life of the  
15 compound *in vivo* compared with nucleoside analogues or protease inhibitors alone, (vi) prolonged duration of biological effect, presumably owing to protection of nucleoside analogue from rapid glucuronide formation in the liver of intact animals, and (vii) capacity to conjugate other small molecular weight compounds to the phosphocholine (PC) lipid backbone for treatment of other diseases of the central  
20 nervous system (e.g. Alzheimer's, cancer), in addition to diseases such as AIDS, resulting from virus infection.

Previous studies have established that a PC moiety is an essential component for a phospholipid to exhibit optimal antiviral activity (Piantadosi et al., 1991, J. Med. Chem. 34:1408-1414; Krugner-Higby et al., 1995, AIDS Res. & Human  
25 Retrovir. 11:705-712). Compounds comprising phosphatidic acid, phosphoethanolamine, phosphoalkylpyridine, alcohol, or quaternary amine salt moieties were less active, more toxic, exhibited much lower differential selectivities, or

some combination of these, relative to the corresponding PC lipids. In certain preferred compounds of the invention, a PC moiety is incorporated into the lipid backbone to result in compounds which exhibit optimal antiviral activity, can accumulate into lymphoid tissues, testes, and vaginal secretions, and can pass the blood-brain barrier into the CNS. These anatomical sites serve as important reservoirs of virus during infection by viruses such as HIV-1, and also serve as sources of transmission of drug-resistant mutants.

The invention also includes methods of treating a virus infection in a cell or in a mammal, such as a human, comprising administering to the cell or mammal a compound of the invention in an amount effective to alleviate or eliminate the virus infection or to alleviate a symptom associated with the infection.

The present invention also includes methods and compositions useful in drug delivery for facilitating delivery of a therapeutic agent to a mammalian cell. As used herein, the term "facilitating delivery" or "to facilitate delivery" of a therapeutic agent to a mammalian cell means enhancing the uptake of a therapeutic agent in a mammalian cell to a level higher than the level of uptake of the therapeutic agent in an otherwise identical mammalian cell which is not administered a compound or composition of the invention. The uptake of a therapeutic agent can be enhanced, by way of example and not by limitation, by any one or more of the following means: by bypassing the requirement for a cellular active transport mechanism for uptake of the therapeutic agent into a cell; by providing the therapeutic agent (i.e. a drug) intracellularly in an activated form, (i.e. the monophosphorylated form in the case of a nucleoside analogue anticancer drug) thereby bypassing the requirement for intracellular activation of the therapeutic agent by an enzyme such as an intracellular kinase; by overcoming a physiological barrier to uptake of the therapeutic agent in a desired cell, such as low solubility, poor absorption from the stomach or small intestine, or impermeability to the blood-brain barrier, to enable delivery of the

therapeutic agent to sites not normally accessible thereto (i.e. CNS and lymphoid tissues).

The present invention also includes methods and compositions useful in drug delivery for combating a cancer in a mammal or for treating or alleviating a disease in a mammal. As used herein, the term "combating a cancer" or "to combat a cancer" in a mammal means, for example, any one or more of the following: to increase survival of a mammal, to decrease or arrest tumor size in a mammal, or to increase the time period of remission of cancer regrowth in a mammal, relative to an otherwise identical mammal which was not administered a composition or compound of the invention.

As used herein, the term "therapeutic agent" means any compound or composition, which, upon entering a mammalian cell, is capable of being of benefit in alleviating or treating a disease in a mammal. By way of example and not by limitation, such compounds and compositions include small organic molecules, peptides, nucleoside analogues, anticancer agents, antiviral agents, ribozymes, protease inhibitors, polymerase inhibitors, reverse transcriptase inhibitors, antisense oligonucleotides and other drugs. The disease may be any disease experienced by a mammal. By way of example and not by limitation, such diseases include diseases of the brain, CNS, lymphatic system, reproductive system, cardiovascular system, renal system and liver, among others.

As used herein, "alleviating a disease" means reducing the severity of a symptom of the disease. As used herein, "treating a disease" means reducing the frequency with which a symptom of the disease is experienced by a mammal.

As used herein, the term "anticancer agent" means a therapeutic agent which is capable of exhibiting efficacy at combating a cancer in a mammal or in a mammalian cell, or any compound which is capable of being converted intracellularly

to a compound which is capable of exhibiting efficacy at combating a cancer in a mammal or in a mammalian cell.

The mammalian cell can be any type of mammalian cell, including both cancerous and non-cancerous cells. Examples of preferred cells include, but are not limited to, CNS and lymphoid cells. Preferred lymphoid cells include lymphoma, spleen and thymus cells. Preferred CNS cells include brain cells, astrocytes, and glial cells. The cancer can be any type of cancer in a mammal. Preferably, the cancer is one or more of a carcinoma, a sarcoma, a neuroblastoma, a leukemia, a lymphoma and a solid tumor.

The compositions of the invention include compounds which comprise an alkyl lipid or a phospholipid moiety covalently conjugated with a therapeutic agent. As used herein, the term "alkyl lipid" means that portion of any of the compounds of Formulae I-VI, as described herein without the therapeutic agent moiety.

The invention also includes pharmaceutical compositions and kits for combating a cancer and/or for facilitating delivery of a therapeutic agent to a mammalian cell.

The invention also includes methods which comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to combat a cancer or in an amount effective to facilitate delivery of a therapeutic agent to a mammalian cell.

As used herein, the following terms are defined as follows, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, alkylene, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to.



The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

Compounds of the invention having a chiral center can exist in and be  
5 isolated in distinct optically active or racemic forms. The present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures of such forms of a compound of the invention. Preparation of optically active forms of a compound is well known in the art (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active  
10 starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase). Determination or assessment of antiviral activity can be performed using standard tests described herein or other tests known in the art.


Specific and preferred definitions listed below for radicals and substituents are for illustration only; they do not exclude other defined values or other  
15 values within defined ranges for the radicals and substituents described herein.

C<sub>1</sub>-C<sub>8</sub> alkyl moieties include, for example, methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, sec-pentyl, iso-pentyl, hexyl, sec-hexyl, iso-hexyl, heptyl, sec-heptyl, iso-heptyl, and octyl moieties. C<sub>1</sub>-C<sub>8</sub> alkoxy moieties include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-  
20 butoxy, pentoxy, sec-pentoxy, iso-pentoxy, hexyloxy, sec-hexyloxy, heptoxy, sec-heptoxy, iso-heptoxy, and octyloxy moieties. C<sub>1</sub>-C<sub>8</sub> alkylene moieties include, for example, methylene, ethylene, propylene, isopropylene, butylene, iso-butylene, sec-butylene, pentylene, sec-pentylene, iso-pentylene, hexylene, sec-hexylene, iso-hexylene, heptylene, sec-heptylene, iso-heptylene, and octylene moieties. C<sub>6</sub>-C<sub>15</sub> alkyl  
25 moieties include, for example, hexyl, heptyl, sec-heptyl, iso-heptyl, octyl, sec-octyl, iso-octyl, nonyl, sec-nonyl, iso-nonyl, decyl, sec-decyl, iso-decyl, undecyl, sec-undecyl, iso-undecyl, dodecyl, sec-dodecyl, iso-dodecyl, tridecyl, sec-tridecyl, iso-

tridecyl, tetradecyl, sec-tetradecyl, iso-tetradecyl, and pentadecyl moieties. C<sub>6</sub>-C<sub>15</sub> alkylene moieties include, for example, hexylene, heptylene, sec-heptylene, iso-heptylene, octylene, sec-octylene, iso-octylene, nonylene, sec-nonylene, iso-nonylene, decylene, sec-decylene, iso-decylene, undecylene, sec-undecylene, iso-undecylene, 5 dodecylene, sec-dodecylene, iso-dodecylene, tridecylene, sec-tridecylene, iso-tridecylene, tetradecylene, sec-tetradecylene, iso-tetradecylene, and pentadecylene moieties. C<sub>8</sub>-C<sub>12</sub> alkyl moieties include, for example, octyl, sec-octyl, iso-octyl, nonyl, sec-nonyl, iso-nonyl, decyl, sec-decyl, iso-decyl, undecyl, sec-undecyl, iso-undecyl, and dodecyl moieties. C<sub>8</sub>-C<sub>12</sub> alkylene moieties include, for example, octylene, sec-octylene, iso-octylene, nonylene, sec-nonylene, iso-nonylene, decylene, sec-decylene, 10 iso-decylene, undecylene, sec-undecylene, iso-undecylene, and dodecylene moieties.

The present invention includes compounds, which exhibit antiviral activity and are particularly useful because they exhibit antiviral activity against drug-resistant viruses. These compounds are also useful in drug delivery for treating or 15 alleviating a disease and for facilitating delivery of a therapeutic agent to a mammalian cell. Accordingly, the invention includes a compound having the chemical structure of Formula I or a pharmaceutically acceptable salt thereof.

Formula I is



(I)

wherein

n and m are each independently 0 or 1, but n and m are not both 0;

5  $\text{R}^1$  is  $(\text{C}_1\text{-C}_{16})$  alkyl, branched alkyl, alkenyl or alkynyl if n is 0 and  $(\text{C}_1\text{-C}_{16})$  alkylene, alkenyl or alkynyl if n is 1;

$\text{R}^2$  is  $(\text{C}_1\text{-C}_{16})$  alkyl, branched alkyl, alkenyl or alkynyl if m is 0 and  $(\text{C}_1\text{-C}_{16})$  alkylene, alkenyl or alkynyl if m is 1;

$\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  are each independently  $(\text{C}_1\text{-C}_8)$  alkylene;

10  $\text{R}^6$ ,  $\text{R}^7$  and  $\text{R}^8$  are each independently  $(\text{C}_1\text{-C}_8)$  alkyl;

$\text{X}^1$  and  $\text{X}^2$  are each independently S, O,  $\text{NHC=O}$ ,  $\text{OC=O}$  or NH;

$\text{X}^3$  is O or S;

$\text{E}^1$  is H, S, halo or  $\text{N}_3$ ;

$\text{Z}^1$  is H, S, or halo; or  $\text{E}^1$  and  $\text{Z}^1$  together are a covalent bond;

15  $\text{E}^2$  is H, S, halo, or  $\text{N}_3$ ;

$\text{Z}^2$  is H, S, or halo; or  $\text{E}^2$  and  $\text{Z}^2$  together are a covalent bond, and

D<sup>1</sup> and D<sup>2</sup> are each independently selected from the group consisting of purine, pyrimidine, adenine, thymine, cytosine, guanine, hypoxanthine, inosine, uracil and ring modifications thereof, including O, N, and S substitutions.

In Formula I, each alkyl, alkylene, branched alkyl, alkenyl, alkynyl, adenine, thymine, cytosine, guanine, pyrimidine, purine, hypoxanthine, inosine and uracil of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, D<sup>1</sup>, and D<sup>2</sup> can, optionally, be substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of halo, nitro, trifluoro, trifluoromethyl, trifluoromethoxy, (C<sub>1</sub>-C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

The following are examples of definitions for radicals and substituents of Formula I in preferred embodiments. These examples are not limiting, but are instead provided as examples of several preferred embodiments which are included in the invention.

In preferred embodiments, R<sup>1</sup> can be one of (C<sub>2</sub>-C<sub>16</sub>) alkylene, -(CH<sub>2</sub>)<sub>12</sub>-, and -CH=CH-. In these embodiments, R<sup>1</sup> is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

In preferred embodiments, R<sup>2</sup> can be one of (C<sub>2</sub>-C<sub>16</sub>) alkylene, -(CH<sub>2</sub>)<sub>8</sub>-, -(CH<sub>2</sub>)<sub>9</sub>-, -(CH<sub>2</sub>)<sub>10</sub>-, -(CH<sub>2</sub>)<sub>11</sub>-, -(CH<sub>2</sub>)<sub>12</sub>-, and -CH=CH-. In these embodiments, R<sup>2</sup> is optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

R<sup>3</sup> is preferably -CH<sub>2</sub>CH<sub>2</sub>-, optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-C<sub>8</sub>)

alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

R<sup>4</sup> is preferably -CH<sub>2</sub>-, optionally substituted with 1 or 2, substituents selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

R<sup>5</sup> is preferably -CH<sub>2</sub>-, optionally substituted with 1 or 2 substituents selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

In one preferred embodiment, each of R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> is -CH<sub>3</sub>, each optionally substituted with 1 or 2 substituents selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

X<sup>1</sup> is preferably S, O or NHC=O.

X<sup>2</sup> is preferably S, O or NHC=O.

X<sup>3</sup> is preferably O or S.

E<sup>1</sup> is preferably N<sub>3</sub>, S, or H.

Z<sup>1</sup> is preferably H.

E<sup>2</sup> is preferably N<sub>3</sub>, S or H.


Z<sup>2</sup> is preferably H.

D<sup>1</sup> is preferably cytosine, guanine, inosine or thymine, wherein D<sub>1</sub> is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

D<sup>2</sup> is preferably cytosine, guanine, inosine or thymine, wherein D<sub>2</sub> is optionally substituted with 1, 2, 3 or 4 substituents selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

The invention also includes a compound, which exhibits antiviral activity having the chemical structure of Formula II or a pharmaceutically acceptable salt thereof. This compound is also useful in drug delivery for treating or alleviating a disease or virus infection in a mammal. This compound is also useful for facilitating delivery of a therapeutic agent to a mammalian cell.

Formula II is



wherein,

- R<sup>1</sup> is (C<sub>6</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;
- R<sup>2</sup> is (C<sub>4</sub>-C<sub>12</sub>) alkylene;
- R<sup>3</sup> is -CH<sub>2</sub>CH<sub>2</sub>-;
- R<sup>5</sup> is -CH<sub>2</sub>-;
- R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each CH<sub>3</sub>;
- X<sup>1</sup> and X<sup>2</sup> are each independently S, O or NHC=O;


$E^2$  is H or  $N_3$ , and

$D^2$  is selected from the group consisting of thymine, cytosine, guanine and inosine.

In Formula II, each alkyl, branched alkyl, alkenyl, alkynyl, thymine, cytosine, guanine, and inosine of  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ , and  $D^2$  can, optionally, be substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of halo, nitro, trifluoromethyl,  $(C_1-C_8)$  alkyl,  $(C_1-C_8)$  alkoxy, aryl, and  $N(R^a)(R^b)$ , wherein  $R^a$  and  $R^b$  are each independently selected from the group consisting of H and  $(C_1-C_8)$  alkyl.

The present invention also includes compounds, which exhibit antiviral activity and are useful in drug delivery for treating or alleviating a disease or virus infection or combating a cancer in a mammal. These compounds are also useful for facilitating delivery of a therapeutic agent to a mammalian cell. Accordingly, the invention includes a compound having the chemical structure of Formula III or a pharmaceutically acceptable salt or a prodrug thereof.

Formula III is



(III)

wherein,

$R^{11}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;

$R^{12}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl or alkynyl;

$R^{12'}$  is (C<sub>1</sub>-C<sub>16</sub>) alkyl, branched alkyl, alkenyl, alkynyl, aryl, phenalkyl,  
5 or alkoxy or hydroxy, anhydride, or hydrogen, with the proviso that when  $R^{12'}$  is not  
hydroxy, it is optionally linked to  $X^{12}$  through a linker moiety L and wherein  $R^{12'}$  is  
optionally terminally substituted with a therapeutic agent, wherein

L is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{11}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

10  $X^{12}$  is -O-, -S-, -NH<sub>2</sub>-, or -NHC(O)-;

$X^{13}$  is -O-, -S-, -CH<sub>2</sub>-, anhydride, or (C<sub>1</sub>-C<sub>16</sub>) alkoxy;

n is 0, 1 or 2;

$R^{13}$  is a therapeutic agent or -R<sup>3</sup>N(R<sup>6</sup>)(R<sup>7</sup>)R<sup>8</sup>;

R<sup>3</sup> is (C<sub>1</sub>-C<sub>8</sub>) alkylene; and

15 R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each independently -H, (C<sub>1</sub>-C<sub>8</sub>) alkyl or (C<sub>1</sub>-C<sub>8</sub>)

alkoxy.

In Formula III, each alkyl, branched alkyl, alkenyl, alkynyl, adenine,  
thymine, cytosine, guanine, pyrimidine, purine, hypoxanthine, inosine and uracil of  
 $R^{11}$ ,  $R^{12}$ , and  $R^{13}$  can, optionally, be substituted with 1, 2, 3, or 4 substituents  
20 independently selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-  
C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each  
independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.

In Formula III, if n is 1 or 2, the compound is a phospholipase C  
substrate and is not a phospholipase A substrate. Also, if n is 1 or 2, the compound is  
25 converted to an alkyl lipid and a moiety selected from the group consisting of a  
nucleoside monophosphate and a nucleoside analogue monophosphate intracellularly  
in a mammal, and is not converted to an alkyl lipid and a moiety selected from the



group consisting of a nucleoside monophosphate and a nucleoside analogue monophosphate extracellularly in a mammal.

The conjugate compounds of Formula III can be formulated in pharmaceutical compositions as described herein, which have the advantageous properties of being suitable for oral administration, can be readily absorbed from the gastrointestinal tract, can cross the blood-brain barrier and be of value in the treatment of CNS diseases and cancers. These conjugates can be used in a number of different cell lines including, by way of example and not by limitation, brain tumor cells, lymphoid cells and pancreatic tumor cells.

In compounds of Formula III, which have at least one phosphate group (i.e.,  $n = 1$  or  $2$ ) the phosphate ester linkage is cleaved intracellularly in a mammal by the action of a phospholipase C-like activity to release intracellularly a phospholipid and an anticancer agent. These compounds are substrates of phospholipase C, but not substrates of phospholipase A. Because the phospholipase C activity is intracellular, the conjugates are only converted to a phospholipid and a nucleoside monophosphate intracellularly, and not extracellularly. The metabolism of these compounds by an intracellular phospholipase C-like activity enables the compounds to be used in methods which circumvent the rate limiting step for the activation of nucleoside analogue prodrugs, namely, the conversion of nucleoside analogue to nucleoside analog monophosphate. Because they are metabolized intracellularly to release a nucleoside analogue monophosphate, the administration of these compounds results in the ability to provide an anticancer agent which can be effective in cancer cells which lack a kinase enzyme such as, for example, deoxycytidine kinase, as a mechanism of cellular anticancer drug resistance. Additionally, the phospholipid moiety can affect signal transduction pathways involving protein kinase C and MAP kinase signaling cascades.

5 The released nucleoside monophosphate serves two purposes. First, it  
bypasses the rate limiting step in the activation of several nucleoside prodrugs, namely,  
deoxycytidine kinase. Second, the polar phosphate group "locks" the nucleoside within  
the cell. The phospholipid conjugate also serves as a reservoir for the drug, increasing  
10 the drugs half-life. The capacity to conjugate other small molecular weight compounds  
to the phospholipid backbone for the treatment of other diseases of the central nervous  
system (i.e. Alzheimer's) is also of great utility. For example, an ether-lipid moiety  
can be used as a backbone for conjugation to a variety of therapeutic agents including  
nucleoside analogues, anticancer and antiviral agents, ribozymes and antisense  
15 oligonucleotides. Since the ether-lipid backbone is lipophilic, these conjugates can  
cross the blood-brain barrier and be used as prodrugs in the treatment of CNS diseases,  
such as Alzheimer's and neurologic degenerative diseases. The lipophilic property of  
the conjugates enables them to cross the blood-brain barrier, and thus bypass the  
requirement for an active transport system in the cell in which uptake of the drug is  
20 desired.

In a preferred compound of Formula III,

$R^{12}$  is ( $C_8$ - $C_{12}$ ) alkyl, branched alkyl, alkenyl or alkynyl;

$R^{12'}$  is ( $C_1$ - $C_{16}$ ) phenalkyl or alkoxy or hydroxy or anhydride, with the  
proviso that when  $R^{12'}$  is not hydroxy, it is optionally linked to  $X^{12}$  through an ether  
20 oxygen;

$R^{13}$  is  $-R^3N(R^6)(R^7)R^8$ ; and

$X^{12}$  is  $-O-$ .


In more preferred compounds of Formula III,  $R^{12'}$  is  $-O_2CCH_2CO_2-$ ,  
wherein  $R^{12'}$  is terminally substituted with a therapeutic agent. A particularly preferred  
25 compound of Formula III is described below as Formula VI.

The therapeutic agent may be an anticancer agent or an antiviral agent.  
These agents include protease inhibitors, polymerase inhibitors, and nucleoside

analogues. Preferably, the anticancer agent is selected from the group consisting of gemcitabine, ara-C, 5-azacytidine, cladribine, fluciarabine, fluorodeoxyuridine, cytosine arabinoside, and 6-mercaptopurine. If the anticancer agent is linked to the third carbon, the phosphorus atom of the phosphate moiety is covalently linked in a phosphate ester linkage to the oxygen atom of the 5' hydroxyl group of a sugar moiety of R<sup>13</sup>. A preferred antiviral agent is AZT.

The invention includes additional compounds, which are useful in drug delivery for treating or alleviating a disease or combating a cancer in a mammal. The compounds are also useful for facilitating delivery of a therapeutic agent to a mammalian cell. Accordingly, the invention includes a compound having the chemical structure of Formula IV or a pharmaceutically acceptable salt thereof.

Formula IV is



wherein,

R<sup>21</sup> is (C<sub>6</sub> to C<sub>16</sub>) alkyl, branched alkyl, alkenyl, or alkynyl;

R<sup>22</sup> is (C<sub>1</sub> to C<sub>12</sub>) alkyl, branched alkyl, alkenyl, or alkynyl;

X<sup>21</sup> is O, S, or NHC=O;

X<sup>22</sup> is O, S, or NHC=O;

X<sup>23</sup> is O or S;

n is 1 or 2, and  
R<sup>23</sup> is a therapeutic agent.

In Formula IV, each alkyl, branched alkyl, alkenyl, alkynyl, adenine, thymine, cytosine, guanine, pyrimidine, purine, hypoxanthine, inosine and uracil of  
5 R<sup>21</sup>, R<sup>22</sup>, and R<sup>23</sup> can, optionally, be substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of halo, nitro, trifluoromethyl, (C<sub>1</sub>-C<sub>8</sub>) alkyl, (C<sub>1</sub>-C<sub>8</sub>) alkoxy, aryl, and N(R<sup>a</sup>)(R<sup>b</sup>) wherein R<sup>a</sup> and R<sup>b</sup> are each independently selected from the group consisting of H and (C<sub>1</sub>-C<sub>8</sub>) alkyl.


In preferred compounds of Formula IV,  
10 R<sup>21</sup> is C<sub>12</sub> alkyl;  
R<sup>22</sup> is C<sub>10</sub> alkyl;  
n = 1, and  
R<sup>23</sup> is an anticancer agent.

Preferably, the anticancer agent is selected from the group consisting of  
15 gemcitabine, ara-C, 5-azacytidine, cladribine, fluciarabine, fluorodeoxyuridine, cytosine arabinoside and 6-mercaptopurine, wherein the methylene group of the phosphonate moiety is covalently linked to the oxygen atom of the 5' hydroxyl group of a sugar moiety of R<sup>23</sup>.

The invention includes additional compounds, which are useful in drug  
20 delivery for treating or alleviating a disease or combating a cancer in a mammal. The compounds are also useful for facilitating delivery of a therapeutic agent to a mammalian cell. Accordingly, the invention includes a compound having the chemical structure of Formula V or a pharmaceutically acceptable salt thereof.

Formula V is:

25



wherein,

$\text{R}^{31}$  is ( $\text{C}_1$  to  $\text{C}_{16}$ ) alkyl, branched alkyl, alkenyl, or alkynyl;

$\text{R}^{32}$  is ( $\text{C}_1$  to  $\text{C}_{16}$ ) alkyl, branched alkyl, alkenyl, or alkynyl;

$\text{X}^{31}$  is O, S, or  $\text{NHC}=\text{O}$ ;

$\text{X}^{32}$  is O, S, or  $\text{NHC}=\text{O}$ ;

$\text{X}^{33}$  is  $-\text{OH}$ ,  $-\text{SH}$ , or amino, and

$\text{R}^{33}$  is a therapeutic agent.

In Formula V, each alkyl, branched alkyl, alkenyl, alkynyl, adenine, thymine, cytosine, guanine, pyrimidine, purine, hypoxanthine, inosine and uracil of  $\text{R}^{31}$ ,  $\text{R}^{32}$ , and  $\text{R}^{33}$  can, optionally, be substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of halo, nitro, trifluoromethyl, ( $\text{C}_1$ - $\text{C}_8$ ) alkyl, ( $\text{C}_1$ - $\text{C}_8$ ) alkoxy, aryl, and  $\text{N}(\text{R}^a)(\text{R}^b)$  wherein  $\text{R}^a$  and  $\text{R}^b$  are each independently selected from the group consisting of H and ( $\text{C}_1$ - $\text{C}_8$ ) alkyl.

In preferred compounds of Formula V,

$\text{R}^{31}$  is ( $\text{C}_6$  -  $\text{C}_{16}$ ) alkyl, branched alkyl, alkenyl or alkynyl;

$\text{R}^{32}$  is ( $\text{C}_1$  -  $\text{C}_8$ ) alkyl, branched alkyl, alkenyl or alkynyl, and

$\text{R}^{33}$  is an anticancer agent.

Preferably, the anticancer agent is selected from the group consisting of mitoxanthrone, methotrexate and CPT-11, and is covalently linked via an ester, amido or carbamate linkage to the -SH, OH or amino group of X<sup>33</sup>.

Compounds of Formula I and Formula II and some compounds of  
5 Formula III can be prepared according to procedures known to the skilled artisan (See, for example, Marx et al., 1988, Journal of Medicinal Chemistry 31:858-863; Meyer et al., 1991, Journal of Medicinal Chemistry 34:1377-1383; Morris-Natschke et al., 1986, Journal of Medicinal Chemistry 29:2114-2117; Piantadosi et al., 1991, Journal of Medicinal Chemistry 34:1408-1414; and Surles et al., 1993, Lipids 28:55-57).

10 An example of such a procedure is illustrated in Figures 2-4. The structures presented in the reaction schemes of Figures 2-4 are representative and not meant to limit the compounds of the invention. Modifications to the reactions in Figures 2-4 using different compounds are apparent to the skilled artisan. Briefly, a compound of Formula I or Formula II is prepared by reacting a lipid backbone moiety,  
15 prepared as shown in Figure 2, for example, with an AZT-malonic acid (AZT-MA) moiety, for example, prepared as shown in Figure 3. Synthetic methods for the preparation of a lipid backbone as described in Figure 2 are known in the art. For example, the synthesis method for preparing a lipid backbone for a thiophosphocholine is described in Morris-Natschke et al., 1986, Journal of Medicinal Chemistry  
20 29(10):2114-2117, except one would substitute the benzyloxy alkyl bromide for the C-2 alkyl chain described in the reference. To prepare an amidophosphocholine, for example, one would follow the synthesis method described in Kucera et al., 1998, Antiviral Chemistry and Chemotherapy, 9:157-165. However, one would substitute C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>O(CH<sub>2</sub>)<sub>8</sub>Br (8-benzyloxyoctyl bromide) for CH<sub>3</sub>(CH<sub>2</sub>)<sub>7</sub>Br (octyl bromide)  
25 described in the reference. To prepare a lipid backbone for various other phosphocholine syntheses, one would follow the synthesis procedures described in Meyer et al., 1991, Journal of Medicinal Chemistry 34(4):1377-1383 and Morris-

Natschke et al., 1993, Journal of Medicinal Chemistry 36(14) 2018-2023. Again, one would substitute the benzyloxy alkyl bromide for the C-2 alkyl chain described in the references.

5 A preferred compound of the invention (e.g. INK-20, a PC lipid-AZT conjugate) can be prepared as described in the Examples herein and depicted in Figure 4 by reacting the lipid backbone moiety generated as shown in Figure 2 with the AZT-malonic acid (AZT-MA) moiety generated as shown in Figure 3. The AZT-MA moiety can be prepared, for example, as described in the Examples herein. Figures 2-4 together illustrate the reaction scheme for preparation of certain preferred compounds  
10 of the invention, wherein AZT is linked to a PC lipid at the terminal functionality of position-2 on a modified thioglycerol backbone. The intermediate thiophosphocholine in Figure 4 has a terminal hydroxyl group on the position-2 side chain, which is used as a site for conjugating AZT to the PC lipid. An antiviral agent such as, for example, AZT or a protease inhibitor can be linked to the PC lipid via a malonic ester. This  
15 synthetic pathway allows manipulation of the rate of esterase-catalyzed hydrolysis of the AZT moiety in the cell by incorporation of substituted malonic linking groups. While not wishing to be bound by any particular theory, it is expected that as with accepted prodrug strategy, the ester bond linking the PC lipid with the AZT moiety is cleaved by the action of esterase-like activity *in vivo*, thereby releasing both active  
20 antiviral agents (e.g. nucleoside or protease inhibitor and PC lipid) inside treated cells (See Chapter 47, "Chemotherapy of Microbial Agents," pp. 1130 and 1141, respectively, in Goodman and Gilman, 1996, "The Pharmacological Basis of Therapeutics", Ninth Ed.).

The following compounds are illustrative of compounds having  
25 structures according to one or both of Formula I, Formula II, and Formula III, as described herein. These compounds can be prepared by the procedures described herein, or by variations thereof which are apparent to those skilled in the art in view of

the instant disclosure. Exemplary compounds include INK-20, INK-25 and INK-26. The chemical structures of these compounds are depicted in Table 1 herein.

Other compounds of Formula III, and compounds of Formulae IV and V can be prepared according to procedures known to the skilled artisan. An example of such a procedure is described, for example, in Piantadosi et al., 1991, J. Med. Chem. 34:1408-1414. The synthesis of a compound of Formula V involves direct esterification of the lipid portion with the therapeutic agent rather than conjugation of the therapeutic agent with the phosphatidic acid portion of Formulae III and IV.

Exemplary compounds having structures according to Formulae III, IV and V, are described herein in the Figures. These compounds can be prepared by the procedures described herein, or by variations thereof which are apparent to those skilled in the art in view of the instant disclosure. Structural formulae of exemplary compounds are shown in Figure 7 (Formula III), Figure 8 (Formula IV), and Figure 9 (Formula V).

The compounds of the present invention can be prepared in the form of a pharmaceutically acceptable salt or a non-pharmaceutically acceptable salt. Non-pharmaceutically acceptable salts are useful, for example, as intermediates for preparation of a pharmaceutically acceptable salt. When the compounds are sufficiently basic or acidic to form stable non-toxic acid or base salts, the compounds may be prepared as a pharmaceutically acceptable salt. Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesirable toxicological effects.

Examples of such salts are acid addition salts formed with inorganic acids, for example, hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids and the like; salts formed with organic acids such as acetic, oxalic, tartaric, succinic, maleic, fumaric, gluconic, citric, malic, methanesulfonic, p-toluenesulfonic, naphthalenesulfonic, and polygalacturonic acids, and the like; salts formed from



elemental anions such as chlorine, bromine, and iodine; salts formed from metal hydroxides, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, and magnesium hydroxide; salts formed from metal carbonates, for example, sodium carbonate, potassium carbonate, calcium carbonate, and magnesium carbonate; salts formed from metal bicarbonates, for example, sodium bicarbonate and potassium bicarbonate; salts formed from metal sulfates, for example, sodium sulfate and potassium sulfate; and salts formed from metal nitrates, for example, sodium nitrate and potassium nitrate.

Pharmaceutically acceptable and non-pharmaceutically acceptable salts may be prepared using procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid comprising a physiologically acceptable anion. Alkali metal (for example, sodium, potassium, or lithium) or alkaline earth metal (for example, calcium) salts of carboxylic acids can also be made.

The compounds of Formulae I -VI can be formulated as pharmaceutical compositions and administered to a mammal, such as a human patient by a chosen route of administration. Pharmaceutical compositions that are useful in the methods of the invention can be prepared, packaged, or sold in a variety of formulations which can be suitable for one or more routes of administration such as, for example, oral, intravenous, intramuscular, topical, subcutaneous, rectal, vaginal, parenteral, pulmonary, intranasal, buccal, ophthalmic, or another route of administration. Other contemplated formulations include projected nanoparticles, liposomal preparations, resealed erythrocytes containing the active ingredient, and immunologically-based formulations.

Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such

compositions are generally suitable for administration to animals of all sorts.

Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and

5 perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and other primates and mammals including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.

10           Thus, the present compounds can be systemically administered (e.g. orally) in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They can be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or incorporated directly into the food of the patient's diet. For oral therapeutic administration, the active compound can be  
15 combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1 % (w/w) of active compound. The percentage of the compositions and preparations can, of course, be varied, for example from about 0.1 % to nearly 100 % of the weight of a given unit dosage form.  
20 The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained upon administration.

          The tablets, troches, pills, capsules, and the like can also contain one or more of the following: binders such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch,  
25 potato starch, alginic acid, and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, fructose, lactose, or aspartame; and a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the unit dosage form

is a capsule, it can contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials can be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules can be coated with gelatin, wax, shellac, sugar, and the like. A syrup or elixir can contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye, and flavoring such as cherry or orange flavor. Of course, any material used in preparing a unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound can be incorporated into sustained-release preparations and devices.

The active compound can be administered orally, intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a non-toxic surfactant. Dispersions can be prepared in glycerol, liquid polyethylene glycols, triacetin, mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent growth of microorganisms.

Pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. The ultimate dosage form should be sterile, fluid, and stable under conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by formation of liposomes, by the maintenance of the required particle size (in the case of dispersions) or by use of one or more surfactants.

Microbial growth can be prevented using various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers, or sodium chloride. Prolonged absorption of the injectable compositions can  
5 be achieved using agents which delay absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compound in the required amount in an appropriate solvent, optionally with one or more of the other ingredients enumerated above, followed by filter sterilization. In the  
10 case of sterile powders for preparation of sterile injectable solutions, preferred methods of preparation include vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient and any additional desired ingredient present in the previously sterile-filtered solution(s).

A pharmaceutical composition of the invention may be prepared,  
15 packaged, or sold in a formulation suitable for rectal administration. Such a composition may be in the form of, for example, a suppository, a retention enema preparation, and a solution for rectal or colonic irrigation.

Suppository formulations may be made by combining the active ingredient with a non-irritating pharmaceutically acceptable excipient which is solid at  
20 ordinary room temperature (i.e. about 20°C) and which is liquid at the rectal temperature of the subject (i.e. about 37°C in a healthy human). Suitable pharmaceutically acceptable excipients include, but are not limited to, cocoa butter, polyethylene glycols, and various glycerides. Suppository formulations may further comprise various additional ingredients including, but not limited to, antioxidants and  
25 preservatives.

Retention enema preparations or solutions for rectal or colonic irrigation may be made by combining the active ingredient with a pharmaceutically acceptable

liquid carrier. As is well known in the art, enema preparations may be administered using, and may be packaged within, a delivery device adapted to the rectal anatomy of the subject. Enema preparations may further comprise various additional ingredients including, but not limited to, antioxidants and preservatives.

5                   A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for vaginal administration. Such a composition may be in the form of, for example, a suppository, an impregnated or coated vaginally-insertable material such as a tampon, a douche preparation, or a solution for vaginal irrigation.

10                   Methods for impregnating or coating a material with a chemical composition are known in the art, and include, but are not limited to methods of depositing or binding a chemical composition onto a surface, methods of incorporating a chemical composition into the structure of a material during the synthesis of the material (i.e. such as with a physiologically degradable material), and methods of  
15                   absorbing an aqueous or oily solution or suspension into an absorbent material, with or without subsequent drying.

                  Douche preparations or solutions for vaginal irrigation may be made by combining the active ingredient with a pharmaceutically acceptable liquid carrier. As is well known in the art, douche preparations may be administered using, and may be  
20                   packaged within, a delivery device adapted to the vaginal anatomy of the subject. Douche preparations may further comprise various additional ingredients including, but not limited to, antioxidants, antibiotics, antifungal agents, and preservatives.

                  A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for pulmonary administration via the buccal  
25                   cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, and preferably from about 1 to about 6 nanometers. Such compositions

are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder or using a self-propelling solvent/powder-dispensing container such as a device comprising the active ingredient dissolved or suspended in a low-boiling propellant in a sealed container. Preferably, such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. More preferably, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions preferably include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.

Low boiling propellants generally include liquid propellants having a boiling point of below 65°F at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non-ionic or solid anionic surfactant or a solid diluent (preferably having a particle size of the same order as particles comprising the active ingredient).

Pharmaceutical compositions of the invention formulated for pulmonary delivery may also provide the active ingredient in the form of droplets of a solution or suspension. Such formulations may be prepared, packaged, or sold as aqueous or dilute alcoholic solutions or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration

preferably have an average diameter in the range from about 0.1 to about 200 nanometers.

The formulations described herein as being useful for pulmonary delivery are also useful for intranasal delivery of a pharmaceutical composition of the invention.

Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered in the manner in which snuff is taken i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nares.

Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may further comprise one or more of the additional ingredients described herein.

A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1-1.0% (w/w) solution or suspension of the active ingredient in an aqueous or oily liquid carrier. Such drops may further comprise buffering agents, salts, or one or more other of the additional ingredients described herein. Other ophthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form or in a liposomal preparation.

For topical administration, the present compounds can be applied in pure form, i.e., as a liquid. However, it will generally be desirable to administer the compounds to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, and the like. Useful liquid carriers include water, alcohols, glycols, and blends of two or more of these, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of  
5 non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize properties for a given use. The resulting liquid compositions can be applied using absorbent pads, used to impregnate bandages or other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts and  
10 esters, fatty alcohols, modified celluloses, or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

Examples of useful dermatological compositions which can be used to deliver the compounds of the invention to the skin are disclosed in Jacquet et al. (U.S.  
15 Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

Accordingly, the invention includes pharmaceutical compositions comprising one or more compounds of Formula I, Formula II, Formula III, Formula IV  
Formula V, Formula VI, or any combination thereof, or a pharmaceutically acceptable  
20 salt thereof, in combination with a pharmaceutically acceptable carrier.

In a preferred embodiment, the pharmaceutical composition is adapted for oral, topical, or parenteral administration to a mammal such as a human, and comprises one or more compounds of Formula I, Formula II, Formula III, Formula VI,  
or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount  
25 effective to treat a virus infection in a mammal or in a cell, particularly wherein the virus is HIV, hepatitis virus, or herpes simplex virus.



As used herein, "treatment" of a virus infection can mean, for example, any one or more of the following: inhibiting the replication of the virus, reducing the virus load within a patient, inhibiting formation of infectious progeny virus, inhibiting infectiousness of virus, killing cells harboring virus, interfering with one or more stages of the virus life cycle, inhibiting one or more viral enzymes or inducing production of non-infectious virus particles that can activate an immune response against infectious virus (e.g. autovaccination).

In another preferred embodiment, the pharmaceutical composition is adapted for oral, topical, or parenteral administration to a mammal such as a human, and comprises one or more compounds of Formulae I-VI, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to combat a cancer in a mammal and/or to facilitate delivery of a therapeutic agent to a mammalian cell.

Useful dosages of the compounds of Formulae I-VI for inclusion in the pharmaceutical compositions of the invention can be determined by comparing *in vitro* activity and *in vivo* activity of the compounds in appropriate animal models. Methods for the extrapolation of effective dosages in mice and other animal models to humans are known in the art (see, for example U.S. Pat. No. 4,938,949).

Generally, the concentration of the compound(s) of Formulae I-VI in a liquid composition, such as a lotion, will range from about 0.1 % to about 95 % by weight, preferably from about 0.5 % to about 25 % by weight. The concentration in a semi-solid or solid composition such as a gel or a powder will range from about 0.1 % to 100% by weight, preferably about 0.5 % to about 5 % by weight. Single doses for intravenous injection, subcutaneous, intramuscular or topical administration, infusion, ingestion or suppository will generally be from about 0.001 to about 5000 mg, and be administered from about 1 to about 3 times daily, to yield levels of about 0.01 to about 500 mg/kg, for adults.

The invention also includes one or more compounds of Formula I, Formula II, Formula III, Formula VI, or any combination thereof, in an amount effective to inhibit virus replication in a mammal. The compound of course is therefore useful for inhibiting virus replication in a cell or neutralization (i.e.

5 inactivation) of extracellular virus. Additionally, the invention includes one or more pharmaceutically acceptable salts of a compound of Formula I, Formula II, Formula VI, or any combination thereof, wherein the compound is present in an amount effective to inhibit virus replication in a mammal.

As used herein, to inhibit virus replication in a mammal means to reduce  
10 the virus load in a mammal to a level which is lower than the level of the virus load in an otherwise identical mammal which was not administered the compound. Preferably, virus load in a mammal is reduced by about 1 to 12  $\log_{10}$  or more relative to an otherwise identical mammal which was not administered the compound. Virus load in a mammal can be assessed by a number of methods known in the art such as, for  
15 example, obtaining a tissue or fluid sample from the mammal and assessing the amount of virus or viral components in the mammal contained therein using technology which is either virological, immunological, biochemical or molecular biological in nature and which is well known to the skilled artisan and which are described elsewhere herein. Inhibition of virus replication in a cell is assessed using similar or identical assays as  
20 those used to assess virus load in a mammal.

The invention also includes a kit for administering a composition of the invention (e.g. a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention) to a mammal for treatment of a virus  
25 infection. Preferably, the mammal is a human. The virus infection can be an infection by any one or more of the viruses described herein. The kit comprises the composition of the invention and an instructional material, which describes adventitiously administering the composition to the mammal by any of the routes of administration

described herein. In another embodiment, this kit comprises a (preferably sterile) solvent suitable for dissolving or suspending the composition of the invention prior to administering the compound to the mammal.

As used herein, an "instructional material" includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition of the invention in the kit for any one or more of the following: effecting treatment of a virus infection in a mammal or in a cell; alleviation or treatment of the symptoms of a virus infection in the mammal; combating a cancer in a mammal; or for facilitating delivery of an anticancer agent to a mammalian cell. The instructional material of the kit of the invention may, for example, be affixed to a container which contains the composition of the invention or be shipped together with a container which contains the composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the composition be used cooperatively by the recipient.

The invention also includes a kit for inhibition of virus replication in a cell. The kit comprises a composition of the invention, which can be one or more compounds of Formula I, Formula II, Formula III or any combination thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising one or more compounds of Formula I and Formula II or any combination thereof. The kit also includes an instructional material.

As used herein, inhibition of virus replication in a cell means a reduction in virus replication in a cell to a level lower than the level in an otherwise identical cell which was not administered the composition of the invention. Preferably, the reduction in virus replication is by about 90 to about 99.9 % relative to the otherwise identical cell which was not administered the composition of the invention. The level of virus replication in a cell and therefore virus load in a mammal that is also

being assessed, can be assessed by any one of numerous methods known to the skilled artisan. For example, the level of virus replication in a cell can be assessed by evaluating the number of virus particles or amount of a viral component, such as a viral protein, a viral enzyme, or viral nucleic acid, in the cell or in fluid or debris associated with the cell. The number of infectious virus particles in a cell can be evaluated, for example, in a plaque assay. The level of a viral component such as a viral protein or enzyme in a cell can be evaluated using standard analytical techniques of protein biochemistry, such as, for example, using an activity assay for a viral enzyme, or using Western blotting or quantitative gel electrophoresis for a viral protein. Viral nucleic acid levels in a cell can be evaluated using standard analytical techniques such as Northern blotting and Southern Blotting or quantitation by polymerase chain reaction (PCR).

The invention includes methods for treatment of a virus infection in a mammal. The methods comprise administering to the mammal one or more compounds of Formula I, Formula II, Formula III, Formula VI, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the virus infection. The compound may be administered by any of the methods described herein. Preferably, the mammal is a human. The virus infection may be caused by any type of virus. Preferably, the virus infection results from infection by a virus selected from the group consisting of HIV-1, HIV-2, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis G virus, herpes simplex virus type 1, herpes simplex virus type 2, varicella-zoster virus, cytomegalovirus, rhinovirus, Epstein Barr virus, human herpes virus type 6, human herpes virus type 7 and human herpes virus type 8, parainfluenza viruses and respiratory syncytial viruses.

The invention also includes methods of treating a virus infection in a mammal by contacting the virus *in vitro*, *in vivo* or *ex-vivo* with one or more

compounds of Formula I, Formula II, Formula III, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the virus infection (e.g. to inhibit virus replication, infectivity, life cycle processes or pathogenesis). Methods for testing the antiviral activity of a compound *in-vitro* are known to the skilled artisan, and are described, for example, in Kucera et al., 1990, AIDS Res. and Human Retrovir. 6:494.

The invention further includes methods of using one or more compounds of Formula I, Formula II, Formula III, Formula VI, or any combination thereof, or a pharmaceutically acceptable salt thereof, in medical therapy (preferably for use in treating a virus infection) or for the manufacture of a medicament useful for the treatment of a virus infection.

The invention also includes methods of inhibiting virus replication in a cell. The methods comprise administering to the cell one or more compounds of Formula I, Formula II, Formula III, Formula VI or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit virus replication in the cell. Inhibition of virus replication in a cell, as described herein, means a reduction in virus replication in a cell to a level lower than the level in an otherwise identical cell, which was not administered the compound of the invention. Preferably, the reduction in virus replication is by about 90 % to about 99.9 % relative to the otherwise identical cell, which was not administered the compound of the invention. The level of virus replication in a cell can be assessed by any one of the methods known to the skilled artisan described herein.

The invention also includes one or more compounds of Formulae I-VI, or any combination thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is present in an amount effective to facilitate delivery of a therapeutic agent to a mammalian cell. Preferably, the therapeutic agent is an anticancer agent, an antiviral agent, a protease inhibitor, a polymerase inhibitor, or a nucleoside analogue.

The protease inhibitors include 2, 4-dioxo-4- (3-hydroxy-phenyl) butyric acid compounds.

In a preferred embodiment, the compound is suspended in a pharmaceutically acceptable carrier and is present in an amount effective to facilitate delivery of a therapeutic agent to a mammalian cell. Preferably, the mammalian cell is in a mammal. Also, preferably, the cell is a cell selected from the group consisting of a CNS cell and a lymphoid cell. Preferred CNS cells include an astrocyte and a glial cell.

Additionally, the invention includes one or more compounds of Formulae III-VI, or any combination thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is present in an amount effective to combat a cancer in a mammal. Preferably, the cancer is one or more of a carcinoma, a sarcoma, a neuroblastoma, a leukemia, a lymphoma, and a solid tumor.

In a preferred embodiment, the compound is suspended in a pharmaceutically acceptable carrier and is present in an amount effective to combat a cancer in a mammalian cell. Preferably, the cell is in a mammal. Also, preferably, the cell is a cell selected from the group consisting of a CNS cell and a lymphoid cell. Preferred CNS cells include an astrocyte and a glial cell.

The invention also includes a drug delivery agent comprising a pharmaceutical composition. The pharmaceutical composition comprises one or more compounds of Formulae I-VI, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to facilitate delivery of a therapeutic agent to a mammalian cell. Preferably, the therapeutic agent is an anticancer agent. Preferably, the cell is in a mammal. Also, preferably, the cell is one or more of a CNS cell and a lymphoid cell.

The invention also includes a drug delivery agent comprising a pharmaceutical composition. The pharmaceutical composition comprises one or more

compounds of Formulae I-VI, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to combat a cancer in a mammal. Preferably, the cancer is one or more of a carcinoma, a sarcoma, a neuroblastoma, a leukemia, a lymphoma, and a solid tumor.

5                    Additionally, the invention includes a method of facilitating delivery of a therapeutic agent to a cell. Preferably, the therapeutic agent is an anticancer agent. The method comprises administering to the cell a pharmaceutical composition comprising one or more compounds of Formulae I-VI, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to facilitate delivery of  
10                    the therapeutic agent to the cell. Preferably, the cell is in a mammal. A preferred cell is a cell selected from the group consisting of a CNS cell and a lymphoid cell.

                    Further, the invention includes a method of combating a cancer in a mammal. The method comprises administering to the mammal a pharmaceutical composition comprising one or more compounds of Formulae III-VI, or any  
15                    combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to combat a cancer in the mammal. Preferably, the mammal is a human. A preferred cancer is a cancer selected from the group consisting of a carcinoma, a sarcoma, a neuroblastoma, a leukemia, a lymphoma, and a solid tumor.

                    The invention also includes a method of treating or alleviating a disease  
20                    in a mammal. The disease can be any disease experienced by a mammal. Preferably, the disease is one or more of a brain disease, a CNS disease, a lymphatic system disease, a reproductive system disease, a cardiovascular disease, a kidney disease and a liver disease. The method comprises administering to the mammal a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable  
25                    salt thereof, in an amount effective to facilitate delivery of a therapeutic agent to a cell in the mammal.

10 The invention also includes a kit for administering a composition of the invention (e.g. a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention) to a mammal for combating a cancer in a mammal. Preferably, the mammal is a human. The cancer can be any of the types  
5 of cancer described herein. The kit comprises the composition of the invention and an instructional material which describes adventitiously administering the composition to the mammal by any of the routes of administration described herein. In another embodiment, this kit comprises a (preferably sterile) solvent suitable for dissolving or suspending the composition of the invention prior to administering the compound to  
10 the mammal.

The invention also includes a kit for facilitating delivery of a therapeutic agent to a mammalian cell. Preferably, the therapeutic agent is an anticancer agent. The kit comprises a composition of the invention, which can be one or more compounds of Formulae I-VI, or any combination thereof, a pharmaceutically  
15 acceptable salt thereof, and a pharmaceutical composition comprising one or more compounds of Formulae I-VI, or any combination thereof. The kit also includes an instructional material.

The invention is now described with reference to the following Examples. These Examples are provided for the purpose of illustration only and the  
20 invention is not limited to these Examples, but rather includes all variations which are evident as a result of the teaching provided herein.

#### Example 1


##### Anti-HIV-1 Activity of Double-Targeting PC lipid-AZT Conjugate Compounds

25 The inhibitory effects of PC lipids, non-PC lipid-AZT conjugates, and double-targeting PC lipid-AZT conjugate compounds of the invention on replication of HIV-1 virus in cells was examined using the plaque assay procedure described in Kucera et al. (1990, AIDS Research and Human Retroviruses, 6:491). CEM-SS cells



were seeded at 50,000 cells per milliliter in RPMI growth medium as a monolayer in 96-well dishes, inoculated with 50 to 100 plaque forming units of HIV-1 and overlaid with serial dilutions of either PC lipid, non-PC lipid-AZT conjugate, or PC-lipid-AZT conjugate in RPMI-1640 growth medium supplemented with 10% fetal bovine serum.

- 5 The structures of the tested compounds are described in Table 1. AZT and PC lipids were used as positive controls. Plaques were counted after incubating the dishes for five days at 37°C to determine the 50% effective concentration (EC<sub>50</sub>) for the compounds tested. The cytotoxicity of PC lipids, non-PC lipid-AZT conjugates and double targeting PC lipid-AZT conjugates was assessed using the procedure described
- 10 in Kucera et al. (1990, AIDS Res. And Human Retrovir., 6:496, and 1998, Antiviral Chemistry and Chemotherapy, 9:160).



(Formula VI)


15

Table 1

Compound	Value of "q" in Formula VI	Identity of "E" in Formula VI
INK 17	8	-OCH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>
INK-18	8	-OH
INK-19	See structure below	
INK-20	8	-O <sub>2</sub> CCH <sub>2</sub> CO <sub>2</sub> AZT
INK-21	10	-OCH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>


<b>INK-22</b>	10	-OH
<b>INK-23</b>	12	-OCH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>
<b>INK-24</b>	12	-OH
<b>INK-25</b>	10	-O <sub>2</sub> CCH <sub>2</sub> CO <sub>2</sub> AZT
<b>INK-26</b>	12	-O <sub>2</sub> CCH <sub>2</sub> CO <sub>2</sub> AZT

The structure of INK-19 is



5

The structure of INK-20 is



10 In the plaque assay, HIV-1 syncytial plaques are seen as large, multicellular foci (10 to 25 nuclei/syncytium) that appear either brown and granular or clear. Because the number of HIV-1 syncytial plaques was correlated with reverse transcriptase (RT) and p24 core antigen activity in the HIV-1 infected cell overlay fluids, the syncytial plaque assay could be used to quantify the amount of infectious virus. Reverse transcriptase activity was assayed according to the procedure described

15

by Poeisz et al. (1980, Proc. Natl. Acad. Sci. U.S.A. 77:7415). The activity of p24 core antigen induced by HIV-1 infection of CEM-SS cells was measured spectrophotometrically using the commercial Coulter enzyme immunoassay (EIA).

The results of these assays are presented in Table 2. These results demonstrate that the double-targeting PC lipid-AZT conjugate compounds of the invention exhibit a higher differential selectivity (DS = ratio of TC<sub>50</sub> for cytotoxicity to EC<sub>50</sub> for anti-HIV activity) than the PC lipids, the non-PC lipid-AZT conjugates and the positive control, AZT. For example, the compound INK-20 exhibited the highest differential selectivity (DS = 7,666) and anti-HIV-1 activity (0.0009 micromolar) of all the compounds tested, while exhibiting a cytotoxicity (6.9 ± 0.6 micromolar) comparable to AZT. The anti-HIV-1 activity of INK-20 was more than ten-fold higher than AZT.

Table 2

Compound	Cytotoxicity (TC <sub>50</sub> ) (μM)	Anti-HIV-1 Activity (EC <sub>50</sub> ) (μM)	Differential Selectivity
INK-17 <sup>a</sup>	49.1 ± 13.2	0.15 ± 0.13	327
INK-18 <sup>a</sup>	50.0 ± 42	1.92 ± 1.8	26
INK-19 <sup>b</sup>	6.3 ± 1.1	0.006 ± 0.001	1050
INK-20 <sup>c</sup>	6.9 ± 0.6	0.0009 ± 0.00007	7666
INK-21 <sup>a</sup>	57.3 ± 10.8	1.50 ± 0.23	38
INK-22 <sup>a</sup>	> 90.5 ± 13.4	0.39 ± 0.31	> 232
INK-23 <sup>a</sup>	> 100.0 ± 0.0	> 1.46 ± 0.76	> 68
INK-24 <sup>a</sup>	80.6 ± 6.2	0.39 ± 0.39	207
INK-25 <sup>c</sup>	13.6	0.02 ± 0.01	682
INK-26 <sup>c</sup>	11.6	0.02 ± 0.02	580
BM21-1290 <sup>d</sup>	38.5	0.02	1925
AZT	3.7	0.009	411

<sup>a</sup> PC-Lipid

<sup>c</sup> A double-targeting compound of the invention (PC lipid-AZT conjugate)

Data indicating that PC lipids alone can inhibit infectious HIV-1

15

### Sensitivity of AZT-Resistant Human Clinical Isolates of HIV-1 to PC Lipids Alone and Double Targeting PC lipid-AZT Conjugate Compounds

25

exhibited a much lower-fold increase in AZT-resistance among HIV-1 clinical isolates than did AZT alone (about 20-fold versus about 680- to 1,100-fold for AZT).

Table 3

Compound	EC <sub>50</sub> (μM) <sup>a</sup>		Fold-Increase	EC <sub>50</sub> (μM) <sup>a</sup>		Fold-Increase
	Pre-AZT G-762	Post-AZT G-691		Pre-AZT H112-2	Post-AZT G-910	
INK-17	0.26	0.18	0	0.04	0.20	5.1
INK-18	>1.06	0.60	0	0.56	1.04	1.8
INK-19	0.12	1.62	13.5	0.03	>1.7	>55.6
INK-20	0.04	0.74	18.6	0.02	0.44	22.0
AZT	0.001	>1.29	>1.170	0.002	>1.36	>681.7
INK-24	0.19	0.08	0	0.37	0.25	<1.0
INK-25	0.03	0.06	2	0.004	0.01	2.5
INK-26	0.003	0.06	20	0.02	0.03	1.5
AZT	0.002	0.33	165	0.002	0.09	45.0

- 5     <sup>a</sup> EC<sub>50</sub> values represent mean values calculated from 2 to 4 independent tests using duplicate wells for each of 4 serial concentrations of compound per test. ">" indicates that EC<sub>50</sub> was not achieved at the highest concentration tested.

Note--designations such as G-762 and H112-2 in the table designate patient codes for the source of the isolates.

10

Example 3

Anti-Herpes Simplex Virus Type 2 Activity of Double-Targeting PC lipid-AZT Conjugate Compounds.

Proof-of-concept of the antiviral activity of the double-targeting PC lipid-AZT conjugate compounds of the invention with respect to herpes simplex virus

type 2 was evaluated and compared with that of PC lipid alone and with acyclovir (positive controls). Serial dilutions of PC lipid, PC lipid-AZT conjugate compound, or acyclovir were evaluated for inhibition of the formation of herpes simplex virus type 2 plaques in Vero cells and  $EC_{50}$  values were calculated from the results obtained.

5 Briefly, the tests for anti-herpes simplex virus (HSV) activity and cytotoxicity of the compounds were performed by seeding  $8 \times 10^4$  monkey kidney cells (Vero) per ml of D-MEM with 10% fetal bovine serum (FBS) in each well of a 12-well dish. The cultures were incubated at  $37^{\circ}C$  to form a complete monolayer. To measure anti-HSV activity and effective concentration  $_{50}$  ( $EC_{50}$ ) each cell monolayer was infected with  
10 HSV diluted in PBS-A containing about 100 plaque forming units (PFU) per 0.1 ml. After virus attachment (1 hr.,  $37^{\circ}C$ ) the infected monolayers were overlaid with E-MEM containing 2% FBS and 0.5% methyl cellulose with or without added serial concentrations of test compound. After 2 days at  $37^{\circ}C$  to allow HSV induced plaque formation, the overlay medium was aspirated, the cell monolayers were fixed with 95%  
15 ethanol, stained with 0.1% crystal violet in 20% methanol and distilled water and the number of PFU in the compound treated cultures was divided by the number of PFU in the untreated controls to determine the percent inhibition of PFU. The  $EC_{50}$  values were calculated using a computer generated program.

To measure cytotoxicity of the compounds, the cell monolayers  
20 (described above) were treated with a serial concentration of test compound for 48 hours at  $37^{\circ}C$  and visually examined after crystal violet staining by light microscopy for changes in cell morphology (cell rounding, shrinking, detachment) compared to an untreated control culture. The cytotoxicity ( $TC_{50}$ ) represents the lowest serial concentration of test compound that caused a detectable change in cell morphology in  
25 at least 25% of the cells.

The results of these experiments are presented in Table 4. These results indicate that PC lipid-AZT conjugate compounds of the invention are metabolized

intracellularly to release two drugs which can target the virus life cycle. The PC lipid compound INK-24 and the AZT conjugate corresponding to INK-24 (i.e. INK-26) both exhibit selective activity against herpes simplex virus type 2, exhibiting EC<sub>50</sub> values of 13.8 and 12.0 micromolar, respectively. By comparison, the range of EC<sub>50</sub> values for acyclovir were 12.5, 14.5 and 6.67 micromolar in replicate tests. Because herpes simplex virus is not expected to be inhibited by AZT, the observed inhibition of the virus by INK-26 is most likely due to intracellular metabolism of INK-26, leading to release of biologically active PC lipid. PC lipid should exhibit activity against the herpes simplex virus in a manner and to a degree similar to the anti-herpes virus activity of INK-24. Cytotoxicity attributable to the double-targeting compound INK-26 appeared to be no worse than that of the positive control (acyclovir) and the PC lipid compound INK-24.

Table 4

Compound	Cytotoxicity (TC <sub>50</sub> ) ( $\mu$ M)	Anti-Herpes Simplex Activity (EC <sub>50</sub> ) <sup>a</sup> ( $\mu$ M)
INK-17	toxic @ 4	>4
INK-18	ND	ND
INK-19	>20	>20
INK-20	toxic @ 20	>20
INK-21	toxic @ 20	>20
INK-22	toxic @ 20	>20
INK-23	>20	>20
INK-24	>20	13.9, 13.8
INK-25	toxic @ 20	>20
INK-26	>20	12.0
Acyclovir control	>20	14.5, 12.5, 6.67

<sup>a</sup> EC<sub>50</sub> values represent mean values obtained from 2 independent tests using duplicate wells for each of four serial concentrations of compound per test. ">" indicates that cytotoxicity or EC<sub>50</sub> was not achieved at the highest concentration tested.

5

Example 4

Data from testing in animals indicating that the phospholipid-AZT conjugate BM21-1290 (see Figure 1A) is orally bioavailable and preferentially taken up into lymphoid tissues (lymphoma, spleen and thymus) is shown in Figure 5. Also, in rodents (mice) receiving oral administration of the conjugate, the compound has exhibited the ability to cross the blood-brain barrier and enter the brain. The data

10



shown in Figure 6 indicates that the concentration of the conjugate compound BM21-1290 in the brain was found to be equivalent to the concentration of BM21-1290 in the plasma. In rodent experiments there was little or no detectable free AZT in the plasma. These data suggest that as a phospholipid-AZT conjugate the AZT is protected from glucuronide formation in the liver. The half-life of the conjugate compound in rodents was 48 hours compared to 30 minutes to 1 hour for AZT alone.

In another set of experiments the metabolism of the compound BM21-1290 using human lymphocytes in tissue culture was assessed. Results of these experiments indicated that the conjugate is metabolized to form an alkyl-lipid plus a phosphorylated species of AZT (i.e., AZT-MP, AZT-DP, AZT-TP and AZT). The predominant AZT species was AZT-MP with lesser amounts of AZT-DP, AZT-TP and AZT. These data suggest that phospholipid-AZT conjugates are metabolized intracellularly by a phospholipase C enzyme to yield a lipid and various species of AZT. AZT-MP can be activated to AZT-TP the inhibitor of HIV-1 induced reverse transcriptase.

Taken together, data from these experiments indicate that phospholipid-AZT conjugates are orally bioavailable, are preferentially taken up by lymphoid tissues, can cross the blood-brain barrier and are subsequently metabolized inside cells to yield an alkyl-lipid and AZT. Both the alkyl-lipid and AZT can function in double targeting the HIV-1 life cycle.

Example 4

Example 5

#### Synthesis of AZT-Malonic Acid

One gram of AZT was dissolved in 30 ml of anhydrous acetonitrile and added dropwise to a solution of 632 mg of malonyl chloride in 20 ml of acetonitrile at 0°C. The reaction mixture was stirred for 2 hours at 0°C then at 8-10°C for 4.5 hours. Thin layer chromatography was used to indicate that the reaction was complete. Water

(4 ml) was added. Solvents were removed in vacuo and the residue purified by silica gel chromatography eluting with  $\text{CHCl}_3$ :MeOH. Pure product was obtained in a 68% yield.

Example 5  
Example 6

Synthesis of INK-20

5 The conditions for the first reaction of the synthesis method for INK-20 is described in Kucera et al., 1998, Antiviral Chemistry & Chemotherapy, 9: 157-165 at p.159 as the two-step synthesis of 3-dodecanamido-2-octyloxypropyl 2-bromethyl phosphate then 3-dodecanamido-2-octyloxypropyl phosphocholine (INK-3). However, 10 the lipid used was 3-dodecylthio-2-(8'-benzyloxyoctyloxy)-1-propanol (see Figure 4) rather than 3-dodecanamido-2-octyloxy-1-propanol as described in the reference. The reactions were the same. Hydrogenation with  $\text{H}_2$ -Pd/C was performed as follows. The phosphocholine [3-dodecylthio-2-(8'-benzyloxyoctyloxy)propyl phosphocholine] was dissolved in 60 ml absolute EtOH and added to 109 mg of palladium black. This 15 reaction mixture was shaken under 59 psi hydrogen gas for 24 hours. The catalyst was removed by filtration through Celite, solvent was removed in vacuo, and the residue was chromatographed on silica gel using  $\text{CHCl}_3$ :MeOH (100:0 to 2:1) as eluent to give 228 mg (43% yield) of [3-dodecylthio-2-(8'-hydroxyoctyloxy)propyl phosphocholine]. AZT-MA (AZT-malonic acid) was then added by the following 20 procedure: One gram of lipid, 192 mg of AZT-MA, 144 mg of dicyclohexylcarbodiimide (DCC), and 9 mg of dimethylaminopyridine (DMAP) were added to 10 ml of DMF. This reaction mixture was stirred at room temperature for 42 hours; copious solid appeared after 18 hours of stirring. The solid was filtered and the solvent removed in vacuo. The residue was chromatographed on silica gel using 25 EtOAc: $\text{CHCl}_3$ :MeOH (2:2:1) as eluent then  $\text{CHCl}_3$ :MeOH (4:1 to 2:1) to give 141 mg (36% yield) of INK-20 ( $R_f \sim 0.3$  in  $\text{CHCl}_3$ :MeOH: $\text{NH}_4\text{OH}$  75:25:5).

Example 6  
~~Example 7~~

Inhibition of Defective HIV-1 in Persistently Infected H9IIIB Cells

a

Inhibition of AZT-resistant clinical isolates of HIV-1 to PC lipid alone (INK-17, INK-18, and INK-24), non-PC Lipid-AZT conjugate (INK-19), and double-targeting PC Lipid-AZT conjugate compounds of the invention (INK-20, INK-25, and INK-26) were evaluated for induction of defective HIV-1 in persistently infected H9IIIB cells.

10 HIV-1 persistently infected H9IIIB cells were washed twice to remove extracellular HIV-1, resuspended in fresh growth medium with or without 1.0 $\mu$ M of compound for a total of 14 days. During the treatment period, the cells were subcultured 1:3 three times a week. In addition, on days 3, 7 and 11, the cells were pelleted to remove extracellular HIV-1 before subculture in fresh growth medium with or without the compound. After 14 or 11 days of treatment, the virus was pelleted (100,000xg, 1 hr, 4C) from the overlay medium to remove free compound, resuspended in fresh medium without compound and assayed for RT activity. The virus suspension was normalized to 500,000 RT DPM and used to infect fresh CEM-SS cells. The infected CEM-SS cells were incubated for a total of 7 or 9 days, and the overlay medium was harvested and assayed for induction of RT activity. The % inhibition of RT activity was used as a measure of defective virus formation during the treatment period. These results are presented in Table 5.

20

Table 5

Compound	DPM-Bkg	% Inhibition
INK-17	2847	58
INK-18	4195	38
INK-19	2508	63
INK-20	2455	64
INK-24	3087	33
INK-25	2140	54
INK-26	1793	61
CP-51	1841	73
AZT	5416	20
AZT	6573	0
Control	6750	0
Control	4630	0

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.

While this invention has been disclosed with reference to specific  
5   embodiments, it is apparent that other embodiments and variations of this invention can  
be devised by others skilled in the art without departing from the true spirit and scope  
of the invention. The appended claims include all such embodiments and equivalent  
variations.